User login
Key clinical point: Survivors of mantle cell lymphoma (MCL), particularly those treated with rituximab plus bendamustine (R-bendamustine), have an increased risk for secondary malignancies (SM).
Major finding: Patients with MCL vs lymphoma-free comparators had significantly higher rates of SM (adjusted hazard ratio [aHR] 1.6; 95% CI 1.4-1.8), with higher rates being observed across all primary treatment groups, ie, the Nordic-MCL2 protocol; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP); R-bendamustine; ibrutinib; lenalidomide; and R-CHOP/cytarabine groups. Treatment with R-bendamustine vs Nordic-MCL2 was independently associated with an increased risk for SM (aHR 2.0; 95% CI 1.3-3.2).
Study details: This population-based retrospective study included adult patients with MCL (n = 1452), each of whom was matched with ≤10 lymphoma-free comparators from the general population (n = 13,992).
Disclosures: This study was funded by the Swedish Cancer Society. I Glimelius and S Eloranta declared receiving research grants, contracts, or support for attending meetings from various sources, including the Swedish Cancer Society. The other authors declared no conflicts of interest.
Source: Abalo KD et al. Secondary malignancies among mantle cell lymphoma patients. Eur J Cancer. 2023;195:113403 (Oct 28). doi: 10.1016/j.ejca.2023.113403
Key clinical point: Survivors of mantle cell lymphoma (MCL), particularly those treated with rituximab plus bendamustine (R-bendamustine), have an increased risk for secondary malignancies (SM).
Major finding: Patients with MCL vs lymphoma-free comparators had significantly higher rates of SM (adjusted hazard ratio [aHR] 1.6; 95% CI 1.4-1.8), with higher rates being observed across all primary treatment groups, ie, the Nordic-MCL2 protocol; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP); R-bendamustine; ibrutinib; lenalidomide; and R-CHOP/cytarabine groups. Treatment with R-bendamustine vs Nordic-MCL2 was independently associated with an increased risk for SM (aHR 2.0; 95% CI 1.3-3.2).
Study details: This population-based retrospective study included adult patients with MCL (n = 1452), each of whom was matched with ≤10 lymphoma-free comparators from the general population (n = 13,992).
Disclosures: This study was funded by the Swedish Cancer Society. I Glimelius and S Eloranta declared receiving research grants, contracts, or support for attending meetings from various sources, including the Swedish Cancer Society. The other authors declared no conflicts of interest.
Source: Abalo KD et al. Secondary malignancies among mantle cell lymphoma patients. Eur J Cancer. 2023;195:113403 (Oct 28). doi: 10.1016/j.ejca.2023.113403
Key clinical point: Survivors of mantle cell lymphoma (MCL), particularly those treated with rituximab plus bendamustine (R-bendamustine), have an increased risk for secondary malignancies (SM).
Major finding: Patients with MCL vs lymphoma-free comparators had significantly higher rates of SM (adjusted hazard ratio [aHR] 1.6; 95% CI 1.4-1.8), with higher rates being observed across all primary treatment groups, ie, the Nordic-MCL2 protocol; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP); R-bendamustine; ibrutinib; lenalidomide; and R-CHOP/cytarabine groups. Treatment with R-bendamustine vs Nordic-MCL2 was independently associated with an increased risk for SM (aHR 2.0; 95% CI 1.3-3.2).
Study details: This population-based retrospective study included adult patients with MCL (n = 1452), each of whom was matched with ≤10 lymphoma-free comparators from the general population (n = 13,992).
Disclosures: This study was funded by the Swedish Cancer Society. I Glimelius and S Eloranta declared receiving research grants, contracts, or support for attending meetings from various sources, including the Swedish Cancer Society. The other authors declared no conflicts of interest.
Source: Abalo KD et al. Secondary malignancies among mantle cell lymphoma patients. Eur J Cancer. 2023;195:113403 (Oct 28). doi: 10.1016/j.ejca.2023.113403